CSD/BSE&NSE/CC/2024-25

January 15, 2025

To To
The Manager The Manager
Department of Corporate Services Listing Department
BSE Limited National Stock Exchange of India Limited
25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051

Scrip Code: 543064 Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015 please find attached herewith the Investor Presentation on JPMC Healthcare
conference Jan 2025.

You are requested to take this information on records.

Thanking you.

Yours faithfully,
For Suven Pharmaceuticals Limited
Digitally signed by
KUNDAN KUNDAN KUMAR JHA
KUMAR JHA Date: 2025.01.15
09:49:52 +05'30'

Kundan Kumar Jha

Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819- Corporate Office: # 202, A-Wing, Galaxy Towers, Plot
821, Andheri Kurla Road, Chakala, Andheri East, No.1, Hyderabad Knowledge City, TSIIC, Raidurg,
Chakala Midc, Mumbai- 400093, Maharashtra, India Hyderabad - 500081 Telangana, India
Tel: 91 22 61539999 Tel: 91 40 2354 9414 / 3311
Email: info@suvenpharm.com I Website: www.suvenpharm.com I CIN : L 2 4 29 9 M H2 0 1 8P L C 42 2 23 6
Suven
Pharmaceuticals Ltd.
…Going Above and Beyond

Investor Presentation
JPMC Healthcare conference Jan 2025
Leading technology-led Innovator Focused Global CDMO

USD 315mn ~37%

STRONG FINANCIAL TRACK-
Revenue LTM Sep’24* EBITDA margins#
RECORD OVER 20+ YEARS

Top 14/20 16 commercial

Global Innovator Relations Molecules
DEEP CUSTOMER Suven+Cohance
RELATIONSHIPS WITH
MARQUEE BIG PHARMA
1000+ 510+
Projects Executed Scientists

EXTENSIVE DEPTH AND

WIDTH OF CHEMISTRY ADC and Oligo
CAPABILITIES
Pharma CDMO
Speciality CDMO Niche Capabilities
and API+

14 Plants, 6 R&D labs Best ESG practices

MULTIPLE ENGINES OF
GROWTH regulatory approved EcoVadis silver

Note: * LTM Revenue Sep’24 Suven & Cohance combined + Sapala proforma + CY24E NJ Bio proforma, INR 84.4/USD Pg. 2
# Last 5 year Avg ; Cohance Lifescience amalgamation under process
 Journey of Platform: We have instrumented a USD 315mn
Global CDMO player
Building a technology-led CDMO - Augmenting scale organically and inorganically
AIML
Mfg
Our niche technology mix to double in Horizon 2
Horizon 3
Horizon 2
Horizon 1 Enzymatic
Moving up the capability curve

synthesis
End to end integrated CRDMO Flow
in ADC with NJ Bio Chemistry Peptides
Niche tech mix

PROTACs
mRNA
Oligo and
Amidites
ADC

HPAPI Niche capabilities

added via M&A

Large commercial
manufacturing
capacities and
regulatory supplies

FY20 FY 25E FY30E

Discovery to commercial Pg. 3

Our Technology Platforms are the key differentiators for us
We have built strong expertise in high growth segments and will continue to invest in these segments organically
and inorganically

Indian CDMOs Global CDMOs

Suven + Cohance Peer 1 Peer 2 Peer 3 EU Peer 1 EU Peer 2 Chinese Peer

Specialized Technologies – Small Molecules

HPAPI – Cytotoxic Drugs      

Controlled Substance 
Flow Chemistry   
Antibody-Drug Conjugates    
PROTACs (Protein Degraders)   
Oligonucleotides and Amidites    
Peptides      
Fermentation   
Standard Small Molecules

Discovery  
Development      
Manufacturing      
Biologics/Large Molecules

Monoclonal Antibodies and Recombinant Technology    

Cell and Gene Therapy  

 Very Strong Capability  Strong Capability  Emerging/Less Established Capability Negligible or Non-existent Capability High growth small molecule segments Pg. 4
Delivered 2x+ superior returns compared to peers

ROCE (%) EBITDA MARGIN (%) PAT MARGIN (%)

2x+
41.0% 36.7%

24.1%

27.5%
25.3%

14.5% 13.9%
19.8% 19.6%

Suven + Domestic Peers Intermational Suven + Domestic Peers Intermational Suven + Domestic Peers Intermational
Cohance Peers Cohance Peers Cohance Peers

Note: 5 years average comparison with Domestic and International peers

Source: Industry financials
Pg. 5
Foundation pillars in place for the Horizon 2 acceleration

1 Presence in East and West 2

Strategic growth drivers – 100+ Our Customer and Quality
years legacy and innovation track record
united
Demonstrated M&A Track Record Top 18
Plants with
Quality
14/20 Global Customer Successful 14 Regulatory
Relations Regulatory approvals
Innovators
Audits R&D Labs scale
6 (in US & India)

GLOBAL PLATFORM

Professionally Run
3 Efforts of BD and R&D Team 4 Management

Strategic
Pharma CDMO R&D team Core team with
Advisory Board
Ready to experience of
BD Team
delivering
leading Science backed accelerate Scientist – 510+ commercial
professionals growth PhDs – 25% 6 Members molecules
Team of Global
Majority PhDs thought leaders With Global
Innovators

Pg. 6
On the back of its unique position Suven is well poised to be a
leader in the Global CDMO space from India
Established a Leading Technology-led innovator
focused Global CDMO in short period of time

Today FY30E FY35E

Revenue* = $315Mn+ Revenue = $1Bn+ Revenue = $2Bn+
60%+ CDMO 80%+ CDMO 90%+ CDMO

Professionally managed team

Scale acquired in short span via

business combinations

Global Presence added with NJ Bio

Niche capabilities in ADC and Oligo. ….. Set to deliver long term sustainable secular growth
NJ Bio acquisition -integrated End to
End CRDMO in ADC
Pg. 7
*LTM Revenue Sep’24 Suven & Cohance combined + Sapala proforma + CY24E NJ Bio proforma, INR 84.4/USD
 Our Growth Engines – Pharma CDMO key driver
Small Molecules, ADCs, Oligonucleotides and Peptides constitute ~52% of New Drug Additions to the Global
Preclinical and Clinical Pipeline in 20241

Pharma CDMO
• Strategic Business Unit to focus on growth
48%# of Sales Specialty acceleration by adding new customers and new
products.
Chemicals
• Dedicated site (Vizag), Space for future
expansion.
10% of Sales
• Relationships with innovators in AgChem,
Cosmetics, Electronic Chemicals and
Photochromic Lens.

Small Molecules ADC* Oligonucleotides

• 16 Commercial Payload –linker – • Amongst few CDMOs
Patented molecules Bioconjugation globally specialized in • Focused portfolio and market leadership in low-
Oligonucleotide and mid volume, specialty APIs with low competitive
• 14/20 Top innovator • Two unique commercial mRNA building blocks intensity
relations; contributing ADCs supplies including Galnac and
>80% revenues Tri-cyclo-DNA • Ongoing augmentation of new product pipeline.
• Expanding payload and
• 7 molecules in products Portfolio and API+* • Built deep cost position through backward
Phase-3 translating Clinical Collaborations –
integration.
into 12 intermediates; added 3 customers and
RFQs growing 2.2x new products 42% of Sales • Top 3 player in 8 out of 10 top molecules in the
• Drug Discovery to API portfolio.
commercial full chain
exposure • Offering end to end vertically integrated solutions
including pellets and formulations.

Source: 1 Citeline Pharmprojects, *Proforma basis subject to the proposed amalgamation of Cohance Lifesciences
# % sales - LTM Revenue Sep’24 Suven & Cohance combined + Sapala proforma + CY24E NJ Bio proforma Pg. 8
Suven is present in the fast growing tech platforms of
ADCs & Oligos
CDMO Market by Technology – Market Size and Projected Growth (2023-29)
40.00%

Suven High-Growth Technology Platforms

35.00%

Protein Degraders
(~$100 Mn)
30.00% Cell and Gene Therapy
ADC
Expected Market Growth (2023-29)

($2.7 Bn)
Oligonucleotides and Nucleic Acid
25.00% ($1.5 Bn)

20.00%

Biologics

15.00% Overall Small Molecules –

Originators and Gx
Peptides
HPAPI
10.00%

5.00% Fermentation
Hormones,
Vaccines
Steroids,
Prostaglandins
0.00%
Controlled Substances

-5.00%
Suven + Cohance Platform presence Pg. 9
Source: Industry data
Significant R&D investments in ADC and Oligos/mRNA in
the clinical pipeline

Global Clinical Active Pipeline R&D pipeline growth (CAGR) 2019-24

25,000
Peptides 2%

Nucleic Acids (Oligos/mRNA) 19%

20,000
Antibody-Drug Conjugates (ADC) 20%

Vaccines and Viral Vectors 8%

15,000
Cell and Gene Therapy 12%

Biologics- Proteins/Antibodies 6%
10,000
Small Molecules - General 4%

Overall Clinical Pipeline 6%

5,000

Pharmaceutical Drug R&D Trends

0 Surging Interest in Targeted Therapies and Genetic

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Treatment leading to uptake in ADCs, Nucleic Acids
Small Molecules Biologics: Proteins/Antibodies Cell and Gene Therapy and Cell/Gene Therapies
Vaccines and Viral Vectors ADC Nucleic Acids: Oligos and mRNA

Peptides Presence in small molecules, contributing >50% of total

addressable R&D pipeline (incl. Oligos, ADCs)
Source: Industry data Pg. 10
Suven uniquely placed to achieve leadership position in
the fast-growing ADC/XDC segment
Expanded ADC offerings to become an integrated End to End CRDMO post acquisition of NJ Bio

Our unique capabilities in ADCs and XDCs ADC/ XDC CDMO market to grow ~3x in next 5 years

Total ADC/XDC outsourcing Market excluding mABs

End-to-end CRDMO Partner from Drug Discovery to Commercialization

Potential MS
Extensive Library of Payload-Linkers for Discovery based on biology
~15%
of the ADC target from a library of 500+ Payload-Linkers
$4B
Integrated Service Offerings: across variety of standard and custom Payloads, Linkers,
Analytical and Bioconjugation

Global leadership in Camptothecin payloads; supplying to 2 commercial ADCs; Current MS

leadership in S-Trione - a key intermediate in camptothecin derivatives ~5%

Uniquely positioned as a Pureplay Payload Supplier: covering 75% of Payload market

$1.4B

Unique breadth of XDC and different payload capabilities – Oligonucleotides,

Radionuclides, Protein Degraders

Capacity augmentation in US & India; Portfolio expansion in new payloads and linker
2024 2029e

Source: : Industry data

Pg. 11
Oligonucleotides is the emerging modality
with fast growing and immense opportunity for higher market share gain

Amongst the few CDMOs globally, supplying complex building blocks for Oligonucleotides

Our Niche in Oligonucleotide segment Oligonucleotides market to grow at 25%+ CAGR

Market Size ($ bn)
Capable of synthesizing a spectrum of modified amidites and nucleosides with
excellent purity with high level of backward integration (15+ steps) Potential MS
~5%
Diversified innovator customer (CDMO and Diagnostic) base with a strong Japan
presence $4B

Current MS
Only supplier of Tricyclo-DNA Amidites in the world​
~1%

Multi-kilo scale synthesis of wide variety of GalNAc compounds supplied to

$1B
Innovators with highest purity profile.

Mastered the chemistry of conformationally constrained nucleic acids and supply to FY24 FY29E
innovators
Amidite and Galnac segments to grow significantly faster than
Capacity augmentation: Investing in a cGMP facility to enhance capacity and drive oligonucleotides market itself
R&D growth
Nucleic acids & oligos vital for R&D in therapeutics, diagnostics, and
synthetic biology.
Forward integrating to oligonucleotide drug substance manufacturing  Market Growth: Moving from rare diseases to high prevalence chronic
indications. Rising use in molecular diagnostics and clinical applications.
 Increased Investments: Pharma and Biotech driving expansion

Source: : Industry data

Pg. 12
ESG Aspirations
We have set multi-dimensional ESG goals for the next 5 years
Our achievement EHS Social Governance To be achieved
ISO 45001:2018
Reduce absolute
Occupational Health and Employees undergo Gold in Eco Vadis
Scope 1+2 emissions Ethical non-
Safety Management 35% from co2 100% Health and Safety
training
ZERO compliance Sustainability assessment
System current level (2030) – 2025

Business continuity
management System ISO Transition to renewable Representation of Regulatory non-
22301 : 2019 20+% energy sources of total 20+% Women workforce by ZERO compliance or Signing third party
energy use by 2027 2030 fines purchase agreement for
renewable power for all
the facilities
British safety council five-
star certification Reduce, reuse and
Employees and Board
Reduce Attrition by Members to
25% recycle specific water <10 FY28 100 acknowledge the
consumption by 2028
% % Code Of Conduct Pharmaceutical Supply
Silver in EcoVadis Chain Initiative (PSCI)
Sustainability assessment membership – 2025
Promote public
Reportable Loss health education
Zero time injury CSR and disease
prevention
Committed to Science
Based Target initiative
(SBTi)

97% score in
TFS audit ESG Profile ESG report for FY 2023-24
Pg. 13
Contact Information

Cyndrella Carvalho, Head - Investor Relations

Suven Pharmaceuticals Ltd

Tel: +91 9823615656

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar

CDR - India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com / rishab@cdr-india.com

Pg. 14
Thank You